Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.

Autor: Deumelandt K; Department of Neurology and National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.; DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Platten M; Department of Neurology and National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.; DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, University Hospital Mannheim, Heidelberg University, Heidelberg, Germany., Ochs K; Department of Neurology and National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.; DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jazyk: angličtina
Zdroj: Neuro-oncology [Neuro Oncol] 2018 Jan 10; Vol. 20 (1), pp. 4-5.
DOI: 10.1093/neuonc/nox169
Databáze: MEDLINE